Stocks and Investing Stocks and Investing
Thu, April 16, 2020
Wed, April 15, 2020

Matthew Harrison Maintained (VRTX) at Buy with Increased Target to $258 on, Apr 15th, 2020


Published on 2024-10-27 03:04:34 - WOPRAI, Matthew Harrison
  Print publication without navigation


Matthew Harrison of Morgan Stanley, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Buy with Increased Target from $251 to $258 on, Apr 15th, 2020.

Matthew has made no other calls on VRTX in the last 4 months.



There are 10 other peers that have a rating on VRTX. Out of the 10 peers that are also analyzing VRTX, 1 agrees with Matthew's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Brian Skorney of "Baird" Downgraded from Buy to Hold and Increased Target to $230 on, Friday, January 31st, 2020


These are the ratings of the 9 analyists that currently disagree with Matthew


  • Gena Wang of "Barclays" Initiated at Buy on, Friday, March 20th, 2020
  • Alethia Young of "Cantor Fitzgerald" Reiterated at Buy with Increased Target to $275 on, Wednesday, March 11th, 2020
  • Brian Abrahams of "RBC Capital" Maintained at Buy with Increased Target to $260 on, Friday, January 31st, 2020
  • Kevin Huang of "CFRA" Maintained at Strong Buy with Increased Target to $286 on, Friday, January 31st, 2020
  • Paul Matteis of "Stifel" Maintained at Strong Buy with Increased Target to $275 on, Friday, January 31st, 2020
  • Ying Huang of "B of A Securities" Maintained at Strong Buy with Increased Target to $295 on, Friday, January 31st, 2020
  • Evan Seigerman of "Credit Suisse" Maintained at Buy with Increased Target to $258 on, Friday, January 31st, 2020
  • Hartaj Singh of "Oppenheimer" Maintained at Buy with Increased Target to $265 on, Wednesday, January 8th, 2020
  • Edward Tenthoff of "Piper Sandler" Maintained at Buy with Increased Target to $284 on, Monday, January 6th, 2020
Contributing Sources